Company Encyclopedia
View More
name
NVO 260116 60 Call
NVO260116C60000.US
News
View More

Key facts: Wegovy GLP-1 pill gains FDA approval; Obesity group calls for better coverage

Novo Nordisk's Wegovy GLP-1 pill gained FDA approval, offering a cost-effective oral option for weight loss, likely boosting the market for GLP-1 drugs.12The Obesity Medicine Association urged better Medicare and Medicaid coverage for obesity drugs, emphasizing collaboration with Novo Nordisk to improve access to treatments for this chronic condition.3

TradingView·
US
NVO
+1.84%
TradingView·
US
NVO
+1.84%

Bollywood stars endorse, prices plummet by 40%! Eli Lilly and Novo Nordisk battle in the Indian weight loss drug market

As global weight loss drug giants compete for the Indian market, Eli Lilly is temporarily leading with its first-mover advantage and celebrity marketing, while Novo Nordisk is launching a counterattack with an aggressive strategy of nearly 40% price cuts. In the face of potential impacts from local generic drugs after the patent expiration in 2026, both companies are accelerating channel penetration and brand building to seize this key market, which is expected to exceed USD 1 billion in scale within two years

Wallstreetcn·
US
NVO
+1.84%
US
LLY
+0.50%
Wallstreetcn·
US
NVO
+1.84%
US
LLY
+0.50%

Top 5 US Stock Gainers/Losers (>100B) (12.24)

Micron Tech(MU) rose 3.77%, with a trading turnover 5.3 Billion USD, and a year-to-date rose 241.6%. Costco Wholesale(COST) rose 2%, with a trading turnover 1.6 Billion USD, and a year-to-date fell 4.4%. ServiceNow(NOW) fell 1.15%, with a trading turnover 595.5 Million USD, and a year-to-date fell 28%. Toyota Motor(TM) fell 1.14%, with a trading turnover 37.0 Million USD, and a year-to-date rose 11.4%.

Top Gainers & Losers·
US
MU
+3.77%
US
COST
+2.00%
US
NVO
+1.84%
Top Gainers & Losers·
US
MU
+3.77%
US
COST
+2.00%
US
NVO
+1.84%

"European Stocks" Pan-European Stoxx 600 closes flat on Christmas Eve, Novo Nordisk surges 9%

On Christmas Eve, trading hours were shortened, and European stock markets saw slight fluctuations on Wednesday. The pan-European Stoxx 600 index closed flat. Novo Nordisk's first GLP-1 tablet has been approved by the U.S. Food and Drug Administration, and the stock price in Europe surged over 9%. The UK FTSE 100 index closed down 18 points or 0.2% at 9,870 points. The German DAX index closed up 56 points or 0.2%, at 24,340 points. The French CAC 40 index closed down less than 1 point, at 8,103 points

AASTOCKS·
US
NVO
+1.84%
AASTOCKS·
US
NVO
+1.84%

FDA approves Novo Nordisk's Wegovy pill for weight loss, based on OASIS trial demonstrating 16.6% mean weight loss. One-third experienced 20%+ weight loss. First GLP-1 receptor agonist for weight management.

The FDA has approved Novo Nordisk's Wegovy pill, an oral GLP-1 receptor agonist, for weight management. The approval follows the OASIS trial, which showed a 16.6% mean weight loss, with one-third of participants losing over 20%. This marks the first oral GLP-1 receptor agonist therapy for weight management. Novo Nordisk plans to launch the pill soon.

Unusual Whales·
US
NVO
+1.84%
Unusual Whales·
US
NVO
+1.84%
Posts
View More

US stocks opened with the Dow down 0.1%, the Nasdaq flat, Nvidia down 0.03%, Tesla up 0.4%, and Novo Nordisk surging 9.6%

In our pre-mkt summary for Subscribers: Stocks held onto gains after a 3-day rally led by tech stocks and the prospect of two more Fed rate cuts in 2026 pushed stocks toward new highs. Today’s delaye...

..............................

$Novo Nordisk AS(NVO.US)

On Monday, Wegovy oral weight-loss drug was approved by the FDA and is expected to be launched in the U.S. in January next year. The product is an oral tablet suitable for peop...

Some + movers in premarket include: $Petco Health and Wellness(WOOF.US) $Urban Outfitters(URBN.US) $Verrica Pharmaceuticals(VRCA.US) $Autodesk(ADSK.US) $Dell Tech(DELL.US) $NetApp(NTAP.US) $Novo Nordi...

© 2025 Longbridge｜Disclaimer